



JC03 Rec'd PCT/PTO 29 MAR 2005

#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/501,566

Filed: 7/15/2004

1<sup>st</sup> Inventor: UNO, Yumiko

For: Novel Proteins and DNAs Thereof

Atty. Dkt. No. 3015 USOP

Art Unit: tba

Examiner: tba

Allowed:

Batch:

Paper No.:

**CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10**

**USPS EXPRESS MAIL LABEL. No. EV 524903879 US**

**DATE IN: March 29, 2005**

**Itemized Papers/Items:**


1. This Postcard and Certificate of Express Mailing (2 pages)
2. Transmittal Form (1 page X 2)
3. Response to Notice of Missing Requirements (1 page), submission of substitute IBM PC/AT format disk containing the CRF of the Sequence Listing, and copy of Notification to Comply with Sequence Listing Requirements (2 pages).

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

MAIL STOP SEQUENCE  
Commissioner for Patents  
P.O. BOX 1450  
Alexandria, VA 22313-1450

on this date, March 29, 2005

Dated: 3/29/05

  
Gail L. Winokur

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
475 Half Day Road  
Lincolnshire, IL 60069 USA



PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

7

Application Number

10/501,566

Filing Date

7/15/2004

First Named Inventor

UNO, Yumiko

Art Unit

tba

Examiner Name

tba

Attorney Docket Number

3015 USOP

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Return Postcard;
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	Certificate of Express Mailing;
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	Substitute IBM PC/AT format disk;
<input checked="" type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	Copy of Notification to Comply
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<b>Remarks</b>	

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 500799.

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	Takeda Pharmaceutical North America		
Signature			
Printed name	Mark Chao, Ph.D., JD		
Date	3/28/05	Reg. No.	37,293

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: <u>Express</u>			
Signature			
Typed or printed name	Gail L. Winokur	Date	3/29/05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail # EV 524903879 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	10/501,566	Art Unit:	tba
Filed:	7/15/04	Examiner:	tba
1 <sup>st</sup> Inventor:	UNO, Yumiko	Allowed:	
For:	Novel Proteins and DNAs Thereof	Batch:	
Atty. Dkt. No.	3015 US0P	Paper No.:	

**Response to Notice to Comply with Sequence Listing Requirements**

**MAIL STOP SEQUENCE**

Commissioner for Patents  
P.O. Box 1450  
Arlington, VA 22313-1450

Sir:

In response to the Notice to Comply with Sequence Listing Requirements mailed February 9, 2005, a copy of the Notice is enclosed.


Applicants respectfully submit another 3.5" IBM PC/AT computer disk containing the CRF file in DOS Text format named 3015US0P\_SEQ.TXT.

The Sequence listing CRF contains the same information as the written sequence listing as originally filed. Further updating of the US Patent Application identifying serial number, filing date and inventor names of the file has been done. The CRF Sequence Listing contains no new matter.

Respectfully submitted

Dated: March 29, 2005

(847)383-3372  
(847)383-3391



Mark Chao, Ph.D., Reg. No. 37,293  
Elaine M. Ramesh, Ph.D., Reg. No. 43032  
Attorney for Applicants  
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
475 Half Day Road  
Lincolnshire, IL 60069 USA




## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/501,566	FIRST NAMED APPLICANT Yumiko Uno	ATTY. DOCKET NO. 3015 USOP
---	-------------------------------------	-------------------------------

23115  
 TAKEDA PHARMACEUTICALS NORTH AMERICA, INC  
 INTELLECTUAL PROPERTY DEPARTMENT  
 475 HALF DAY ROAD  
 SUITE 500  
 LINCOLNSHIRE, IL 60069

INTERNATIONAL APPLICATION NO. PCT/JP03/00311	
I.A. FILING DATE 01/16/2003	PRIORITY DATE 01/18/2002



CONFIRMATION NO. 8263  
 371 FORMALITIES LETTER



\*OC000000015073078\*

Date Mailed: 02/09/2005

### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
  - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
  - APPLICANT MUST PROVIDE:
    - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase PatentIn Software, call (703) 306-2600
  - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

INDIA L EVANS

Telephone: (703) 308-9140 EXT 212

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.

10/501,566

INTERNATIONAL APPLICATION NO.

PCT/JP03/00311

ATTY. DOCKET NO.

3015 USOP

FORM PCT/DO/EO/922 (371 Formalities Notice)